ANL
Adlai Nortye Ltd.
NASDAQ · Healthcare · Biotechnology · KY
$10.38
−5.89%Oct 15, 2026, 11:00 UTC
Adlai Nortye Ltd. entered into a clinical collaboration with Eli Lilly and Merck KGaA to evaluate AN4035 as monotherapy and in combination with cetuximab in an ongoing global Phase I trial.
Source:Sep 8, 2026, 11:00 UTC
Adlai Nortye dosed the first patient in Australia and received U.S. FDA IND clearance for AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC targeting CEACAM5, initiating a global Phase I trial.
Source:Aug 3, 2026, 11:00 UTC
Adlai Nortye announced that it has submitted a clinical trial notification and received HREC approval to start a Phase I clinical trial of its pan-RAS(ON) inhibitor ADC AN4035 in Australia.
Source: